A new iShares fund applies a "quality" strategy to U.S. stocks in an attempt to capture a tiny bit of Warren Buffett's magic.
Using the active share metric, we examine the degree to which these funds' portfolios differ from the benchmark.
Small- and mid-cap holdings top readers' lists of attractive funds that are closed or otherwise unavailable.
Large drugmakers are out of favor, but some good funds are banking on a rebound.
Wide-moat funds were the stars of the recent downturn.
Plus, USAA jettisons GMO on USAA Income Stock, and a new comanager on Gold-rated Jensen Quality Growth.
Joyce is also set to leave GMO. Also, American Century's LIVESTRONG funds withstand Lance Armstrong controversy, Dreyfus' CEO departs, manager changes at Fidelity and American Century, and analyst reductions at UBS Global Asset Management.
In the rush to index, high active share could, paradoxically, be a way to cut volatility.
The market has rarely discounted large, strong companies this cheaply, argue Steven Romick of FPA and Ben Inker of GMO.
Which mutual funds have managed to sidestep the carnage?